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Each year the American Society for Blood andMarrow Transplantation presents Best Abstract Awards to recognize
outstanding research in the basic sciences that contribute to the advancement of the field of blood and marrow
transplantation. The abstracts receiving the award are those that were scored highest by the Abstract Review
Committees. Each award is accompanied by a prize of $1,000.1
TARGETED IN VIVO EXPANSION OF HUMAN MULTIPOTENT AND
LYMPHOID PROGENITORS
Abdel-Azim, H., Zhu, Y., Ge, S., Kohn, D.B., Crooks, G.M. Childrens
Hospital Los Angeles, University of Southern California, Los Angeles, CA.
Delayed immune reconstitution following Hematopoietic Stem
Cell (HSC) transplantation, particularly in the T cell depleted
setting, is associated with increased morbidity and mortality. In
murine studies, lymphoid recovery is accelerated by co-
transplantation of lymphoid progenitors with HSC; however, the
rarity of human lymphoid progenitors in harvested products limits
the clinical usefulness of this approach. We explored the effects of
an inducible cytokine receptor signaling system to expand HSC
and lymphoid progenitors after transplantation. A fusion protein
containing the intracellular signaling domain of Mpl and a dimeriza-
tion domain was constitutively expressed via a lentiviral vector
in human cord blood lympho-myeloid progenitor/stem cells
(CD341CD38-Lin-CD7-, aka ‘‘CD7-’’) and lymphoid progenitors
(CD341CD38-Lin-CD71, aka ‘‘CD71’’). Sublethally irradiated
NOD/SCIDß2 m
null mice were transplanted via intratibial injection
with low numbers of human cells (1 104 CD7- and 6 103 CD71
cells/mouse, n 5 6 per arm) designed to provide minimal baseline
engraftment from unstimulated cells. Intracellular dimerization of
Mpl in target cells was induced in vivo from Day -1, by daily admin-
istration of a diffusible synthetic ligand CID (AP20187). Overall
engraftment of both CD7- multipotent and CD71 lymphoid pro-
genitors, assayed by bioluminescence imaging and FACS, was sig-
nificantly higher in animals treated with CID (P \ 0.007), and
high level engraftment of human cells continued until time of sacri-
fice at 12 weeks. After transplantation of either CD7- or CD71
cells, CID treatment in vivo produced expansion of CD341Lin-
cells.1000 fold; transplanted animals not treated with CID showed
no progenitor expansion. Clonogenic human myelo-erythroid pro-
genitors were identified in the bone marrow harvested only from
CID treated animals transplanted with CD7- cells. Human T cells
were generated on OP9-DL1 stroma from human progenitors iso-
lated from both CD7- and CD71 transplanted animals treated with
CID. Analysis of the CID treated bone marrow in engrafted animals
showed normal human karyotypes, and LAM-PCR, indicated poly-
clonal expansion of the transduced human cells. These data demon-
strate that CID induced Mpl signaling can deliver a profound and
prolonged expansion in both uncommitted and lymphoid-commit-
ted human hematopoietic progenitors. This approach may be suc-
cessful in attaining rapid immune reconstitution following
transplantation, and in targeted gene and cytotherapy.2
IDENTIFICATION OF HUMAN MINOR HISTOCOMPATIBILTY ANTIGENS
(MHA) BY COMBINING BIOINFORMATIC PREDICTION OF PEPTIDE
EPITOPES WITH VALIDATION OF T CELL REACTIVITY IN PATIENT
BLOOD SAMPLES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Ofran, Y.1, Brusic, V.2, Soiffer, R.J.1, Antin, J.H.1, Ritz, J.12
1Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA;
2Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Minor histocompatibility antigens (mHA) are targets of graft ver-
sus host disease (GVHD) and graft versus leukemia (GVL) re-
sponses. Traditional methods for characterization of mHA are
laborious and require the isolation of mHA-specific T cell clones
followed by determination of their peptide-MHC specificity.
Therefore, the number of mHA discovered thus far is small. We re-port a novel method for rapid identification of mHA based on in-
silico prediction of potential class I restricted mHA peptides and
subsequent validation by ELISPOT assay in patient blood samples.
The study was performed in HLA-A*0201 positive patient-donor
pairs and focused on the subset of mHA derived from proteins
encoded by Y-chromosome genes. Peptide sequences of human
protein-coding Y genes were extracted from the NCBI genome da-
tabase. The entire set of Y-encoded protein sequences was screened
for HLA class I binding peptides using IEDB prediction tool (tool-
s.immuneepitope.org/analyze/html/mhc_binding.html). This anal-
ysis produced a list of 9- and 10-mer peptides predicted to bind
HLA-A*0201. Peptides derived from proteins classified as hypo-
thetical and those solely expressed in male tissues (e.g. testis, pros-
tate) were excluded. Peptides with high predicted binding affinity
(#100 nM) were further analyzed using sequence similarity search
(BLAST) against the UniProt database. Peptides having 100%
identity to peptides encoded by paralog genes on any other chromo-
some (mostly  paralogs) were excluded. Selected candidate pep-
tides were synthesized and peptide/HLA-A2 binding was
validated experimentally using two binding assays. T cell reactivity
was measured by IFN-g ELISPOT assay in blood samples from
three male patients with GVHD who received grafts from female
donors. Forty-three peptides, uniquely encoded by Y-chromosome
genes, were identified by in-silico screening. Of these, 41 were syn-
thesized and 39 confirmed as high-affinity binders. The only known
Y-encoded HLA-A2 restricted mHA (FIDSYICQV) was predicted
by the bioinformatic model and T cell reactivity against this epitope
was identified in all 3 patients. At least 2 additional new Y-encoded
mHA were identified in these patients. We have combined bioinfor-
matics with standard immunologic assays and demonstrated the
utility of this approach to the discovery of novel mHA. This ap-
proach can be further generalized by application to other HLA al-
leles as well as to other genetic polymorphisms predicted to result
in immunogenic epitopes.3
MOBILIZATION OF NORMAL MOUSE PROGENITORS AND ACUTE PRO-
MYELOCYTIC LEUKEMIA (APL) CELLS WITH INHIBITORS OF CXCR4
AND VLA-4 IN SPLENECTOMIZED AND UNSPLENECTOMIZED MICE
Ramirez, P.A., Holt, M., Rettig, M., Ritchey, J., DiPersio, J.F.
Washington University, St. Louis, MO.
Background: Normal hematopoietic (HSC) and leukemic stem
cells (LSC) interact with osteoblasts and matrix proteins in the
bone marrow niches. That interaction plays important roles in sur-
vival and proliferation. Significant data indicate that both the
CXCR4 and VLA-4 are involved in HSC and LSC homing and mo-
bilization. Little is known regarding the kinetics and effect of com-
bining inhibitors of CXCR4 and VLA-4 on normal HSC and APL
mobilization. Methods: To evaluate mobilization of HSC, normal
and splenectomized 8 week old 129/B6 F1 mice were treated with
AMD3100 (5 mg/kg sc) and/or a small molecule inhibitor of
VLA-4 (AMD15057; 1 mg/kg iv). APL cells from the spleens of mu-
rine cathepsin G-PML-RARa knock-in mice were genetically mod-
ified with a firefly luciferase-eGFP fusion gene (APLluc) to allow
tracking by BLI and flow cytometry. Mobilization of APL cells
was performed 10 days after iv injection of 106 banked APL cells
into normal and splenectomized 8 week old 129/B6 mice using
the same schedule. Engraftment and expansion of APL was assessed
by WBC, BLI and overall survival. Results: AMD3100 and
AMD15057 resulted in peak mobilization of HSC and APL in 3
hours in normal mice, and in 1–3 hours in splenectomized mice.
Synergism of normal HSC (130 fold over baseline, CFU-GM)1
